232 related articles for article (PubMed ID: 26377682)
41. Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
Yu KPT; Luk HM; Leung GKC; Mak CCY; Cheng SSW; Hau EWL; Chan DKH; Lam STS; Tong TMF; Chung BHY; Lo IFM
Am J Med Genet C Semin Med Genet; 2019 Jun; 181(2):208-217. PubMed ID: 30896080
[TBL] [Abstract][Full Text] [Related]
42. Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.
Bessis D; Miquel J; Bourrat E; Chiaverini C; Morice-Picard F; Abadie C; Manna F; Baumann C; Best M; Blanchet P; Bursztejn AC; Capri Y; Coubes C; Giuliano F; Guillaumont S; Hadj-Rabia S; Jacquemont ML; Jeandel C; Lacombe D; Mallet S; Mazereeuw-Hautier J; Molinari N; Pallure V; Pernet C; Philip N; Pinson L; Sarda P; Sigaudy S; Vial Y; Willems M; Geneviève D; Verloes A; Cavé H
Br J Dermatol; 2019 Jun; 180(6):1438-1448. PubMed ID: 30417923
[TBL] [Abstract][Full Text] [Related]
43. Congenital sensorineural hearing loss as the initial presentation of
Gao X; Huang SS; Qiu SW; Su Y; Wang WQ; Xu HY; Xu JC; Kang DY; Dai P; Yuan YY
J Med Genet; 2021 Jul; 58(7):465-474. PubMed ID: 32737134
[TBL] [Abstract][Full Text] [Related]
44. Pilocytic astrocytoma in a child with Noonan syndrome.
Schuettpelz LG; McDonald S; Whitesell K; Desruisseau DM; Grange DK; Gurnett CA; Wilson DB
Pediatr Blood Cancer; 2009 Dec; 53(6):1147-9. PubMed ID: 19621452
[TBL] [Abstract][Full Text] [Related]
45. Optic nerve pilomyxoid astrocytoma in a patient with Noonan syndrome.
Nair S; Fort JA; Yachnis AT; Williams CA
Pediatr Blood Cancer; 2015 Jun; 62(6):1084-6. PubMed ID: 25585602
[TBL] [Abstract][Full Text] [Related]
46. Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance.
Walton-Betancourth S; Martinelli CE; Thalange NK; Dyke MP; Acerini CL; White S; Camacho-Hübner C; Savage MO
J Endocrinol Invest; 2007 May; 30(5):439-41. PubMed ID: 17598979
[TBL] [Abstract][Full Text] [Related]
47. Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
Padidela R; Camacho-Hübner C; Attie KM; Savage MO
Horm Res; 2008; 70(3):129-36. PubMed ID: 18663312
[TBL] [Abstract][Full Text] [Related]
48. Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height.
Libraro A; D'Ascanio V; Cappa M; Chiarito M; Digilio MC; Einaudi S; Grandone A; Maghnie M; Mazzanti L; Mussa A; Patti G; Scarano E; Spinuzza A; Vannelli S; Wasniewska MG; Ferrero GB; Faienza MF
Front Endocrinol (Lausanne); 2021; 12():761171. PubMed ID: 35002956
[TBL] [Abstract][Full Text] [Related]
49. Acute lymphoblastic leukemia developing in a patient with Noonan syndrome harboring a PTPN11 germline mutation.
Sakamoto K; Imamura T; Asai D; Goto-Kawashima S; Yoshida H; Fujiki A; Furutani A; Ishida H; Aoki Y; Hosoi H
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e136-9. PubMed ID: 24072241
[TBL] [Abstract][Full Text] [Related]
50. Growth hormone therapy in noonan syndrome.
Kelnar CJ
Horm Res; 2000; 53 Suppl 1():77-81. PubMed ID: 10895047
[TBL] [Abstract][Full Text] [Related]
51. Noonan syndrome: rhGH treatment and PTPN11 mutation.
Wu X; Wu J; Yuan Y; Yang L; Yu L
Mol Genet Genomic Med; 2023 Nov; 11(11):e2266. PubMed ID: 37525886
[TBL] [Abstract][Full Text] [Related]
52. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence.
Noonan JA; Kappelgaard AM
Horm Res Paediatr; 2015; 83(3):157-66. PubMed ID: 25503994
[TBL] [Abstract][Full Text] [Related]
54. Cardiac transplantation in children with Noonan syndrome.
McCallen LM; Ameduri RK; Denfield SW; Dodd DA; Everitt MD; Johnson JN; Lee TM; Lin AE; Lohr JL; May LJ; Pierpont ME; Stevenson DA; Chatfield KC
Pediatr Transplant; 2019 Sep; 23(6):e13535. PubMed ID: 31259454
[TBL] [Abstract][Full Text] [Related]
55. Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Chinton J; Huckstadt V; Moresco A; Gravina LP; Obregon MG
Arch Argent Pediatr; 2019 Oct; 117(5):330-337. PubMed ID: 31560489
[TBL] [Abstract][Full Text] [Related]
56. [Genetic identification of a case of Noonan syndrome and treatment with growth hormone].
Pi G; Zúñiga A; Gastaldo E; Ortiz M
Med Clin (Barc); 2014 Apr; 142(8):378-9. PubMed ID: 24054841
[No Abstract] [Full Text] [Related]
57. SHP2 sails from physiology to pathology.
Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
[TBL] [Abstract][Full Text] [Related]
58. Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?
Brasil AS; Malaquias AC; Wanderley LT; Kim CA; Krieger JE; Jorge AA; Pereira AC; Bertola DR
Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):717-22. PubMed ID: 21340158
[TBL] [Abstract][Full Text] [Related]
59. Management of growth failure and other endocrine aspects in patients with Noonan syndrome across Europe: A sub-analysis of a European clinical practice survey.
Edouard T; Zenker M; Östman-Smith I; Ortega Castelló E; Wolf CM; Burkitt-Wright E; Verloes A; García-Miñaúr S; Tartaglia M; Shaikh G; Lebl J
Eur J Med Genet; 2022 Jan; 65(1):104404. PubMed ID: 34896604
[TBL] [Abstract][Full Text] [Related]
60. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.
Digilio MC; Conti E; Sarkozy A; Mingarelli R; Dottorini T; Marino B; Pizzuti A; Dallapiccola B
Am J Hum Genet; 2002 Aug; 71(2):389-94. PubMed ID: 12058348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
